Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in recurrent pericarditis HAMILTON, Bermuda, March 18, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported additional interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1a and IL-1ß signaling. The data were included in a poster presentation at the American College of Cardiology’s (ACC) 68th Annual Scientific Session in New Orleans, LA. Dr. Allan Klein, MD, of Cleveland Clinic and co-principal investigator for the trial, presented Rilonacept in Recurrent Pericarditis: First Efficacy and Safety Da
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024GlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.MarketBeat
- Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Announces Development Indication for AbiprubartGlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.MarketBeat
KNSA
Earnings
- 2/28/24 - Beat
KNSA
Sec Filings
- 4/10/24 - Form PRE
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- KNSA's page on the SEC website